Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/136256
Full metadata record
DC FieldValueLanguage
dc.creatorSilva, V
dc.creatorCerqueira, F
dc.creatorNazareth, N
dc.creatorMedeiros, R
dc.creatorSarmento, A
dc.creatorSousa, E
dc.creatorPinto, M
dc.date.accessioned2021-09-20T10:52:25Z-
dc.date.available2021-09-20T10:52:25Z-
dc.date.issued2019
dc.identifier.issn1424-8247
dc.identifier.urihttps://hdl.handle.net/10216/136256-
dc.description.abstractXanthones have been suggested as prospective candidates for cancer treatment. 1,2-dihydroxyxanthone (1,2-DHX) is known to interfere with the growth of several cancer cell lines. We investigated the effects of 1,2-DHX on the growth of the A375-C5 melanoma cell line and THP-1 human macrophage activity. 1,2-DHX showed a moderate growth inhibition of A375-C5 melanoma cells (concentration that causes a 50% inhibition of cell growth (GI50 ) = 55.0 ± 2.3 µM), but strongly interfered with THP-1 human macrophage activity. Supernatants from lipopolysaccharide (LPS)-stimulated THP-1 macrophage cultures exposed to 1,2-DHX significantly increased growth inhibition of A375-C5 cells, when compared to supernatants from untreated LPS-stimulated macrophages or to direct treatment with 1,2-DHX only. 1,2-DHX decreased THP-1 secretion of interleukin-1ß (IL-1ß) and interleukin-10 (IL-10), but stimulated tumor necrosis factor-a (TNF-a) and transforming growth factor-ß1 (TGF-ß1) production. This xanthone also inhibited nitric oxide (NO) production by RAW 264.7 murine macrophages, possibly through inhibition of inducible NO synthase production. In conclusion, these findings suggest a potential impact of 1,2-DHX in melanoma treatment, not only due to a direct effect on cancer cells but also by modulation of macrophage activity.
dc.description.sponsorshipThis work was partially supported through national funds provided by FCT/MCTES—Foundation for Science and Technology, I.P., from the Minister of Science, Technology, and Higher Education (PIDDAC) and European Regional Development Fund (ERDF) through the COMPETE—Programa Operacional Factores de Competitividade (POFC) programme, under the Strategic Funding UID/Multi/04423/2013, UID/Multi/04423/2019, UID/Multi/04546/2013, and UID/Multi/04546/2019, the project PTDC/MAR-BIO/4694/2014 (reference POCI-01-0145-FEDER-016790; Project 3599—Promover a Produção Científica e Desenvolvimento Tecnológico e a Constituição de Redes Temáticas (3599-PPCDT)) in the framework of the programme PT2020.
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147268/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147386/PT
dc.relation.ispartofPharmaceuticals, vol.12(2):85
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCytokines
dc.subjectMacrophages
dc.subjectMelanoma
dc.subjectXanthones
dc.title1,2-dihydroxyxanthone: Effect on A375-C5 melanoma cell growth associated with interference with THP-1 human macrophage activity
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/ph12020085
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/12/2/85
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-ph12020085.pdf789.09 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons